Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

Posted on

“For nearly 30 years there has been quite literally no advancement in treatments for GBS. This research update, including the participation of two of the founding fathers of our global medical advisor board, offers incredible promise and hope for the GBS community.” –Lisa Butler, Executive Director, GBS|CIDP Foundation International

Check back often as we will share expert opinions and resources for continued advancements.

Read Article Here: